New SPECT and PET Radiopharmaceuticals for Imaging Inflammatory Diseases: A Meta-analysis of the Last 10 Years
Modern molecular nuclear medicine is rapidly developing in the field of imaging of chronic inflammatory diseases, and many new radiopharmaceuticals have been recently described and tested in animals and man. These can detect early pathophysiological changes before the development of anatomical changes and, often, before clinical onset of symptoms. This field includes new radiopharmaceuticals for SPECT and PET use to define new strategies for imaging immune cells as well as tissue modifications induced by the inflammatory process. (Source: Seminars in Nuclear Medicine)
Source: Seminars in Nuclear Medicine - February 4, 2018 Category: Nuclear Medicine Authors: Marta Pacilio, Chiara Lauri, Daniela Prosperi, Agnese Petitti, Alberto Signore Source Type: research
Molecular Imaging of Inflammatory Arthritis and Related Disorders
Rheumatic disorders comprise a number of diseases that range from benign, mildly symptomatic degenerative disease to severe systemic disorders such as giant-cell vasculitis with dramatic consequences such as acute blindness. The former is relatively common, whereas the latter is rare. In between, commonly encountered disorders such as rheumatoid arthritis and the various spondyloarthritides, with or without peripheral enthesitis, are daily challenges for the caring physician. Clinical evaluation is of utmost importance and is constantly described under the form of specialist guidelines in all parts of the world. (Source: S...
Source: Seminars in Nuclear Medicine - January 10, 2018 Category: Nuclear Medicine Authors: Fran çois Jamar, Annibale Versari, Filippo Galli, Frédéric Lecouvet, Alberto Signore Source Type: research
Pathogen-Specific Bacterial Imaging in Nuclear Medicine
When serious infections are suspected, patients are often treated empirically with broad-spectrum antibiotics while awaiting results that provide information on the bacterial class and species causing the infection, as well as drug susceptibilities. For deep-seated infections, these traditional diagnostic techniques often rely on tissue biopsies to obtain clinical samples which can be expensive, dangerous, and has the potential of sampling bias. Moreover, these procedures and results can take several days and may not always provide reliable information. (Source: Seminars in Nuclear Medicine)
Source: Seminars in Nuclear Medicine - December 14, 2017 Category: Nuclear Medicine Authors: Alvaro A. Ordonez, Sanjay K. Jain Source Type: research
Letter From the Guest Editor
From 2014 through 2016, I had the pleasure of organizing, together with Dr Ora Israel, Categorical Seminars on Molecular Imaging of Inflammation and Infection, for the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). These seminars, sponsored by the SNMMI's General Clinical Nuclear Medicine Council, were the genesis of these next two issues of Seminars in Nuclear Medicine. The diagnosis of inflammatory and infectious diseases can be elusive, and imaging tests are often used for confirmation and localization. (Source: Seminars in Nuclear Medicine)
Source: Seminars in Nuclear Medicine - December 11, 2017 Category: Nuclear Medicine Authors: Christopher J. Palestro Source Type: research
Fever of Unknown Origin: the Value of FDG-PET/CT
Fever of unknown origin (FUO) is commonly defined as fever higher than 38.3 °C on several occasions during at least 3 weeks with uncertain diagnosis after a number of obligatory investigations. The differential diagnosis of FUO can be subdivided in four categories: infections, malignancies, noninfectious inflammatory diseases, and miscellaneous causes. In most cases of FUO , there is an uncommon presentation of a common disease. FDG-PET/CT is a sensitive diagnostic technique for the evaluation of FUO by facilitating anatomical localization of focally increased FDG uptake, thereby guiding further diagnostic tests to achiev...
Source: Seminars in Nuclear Medicine - December 8, 2017 Category: Nuclear Medicine Authors: Ilse J.E. Kouijzer, Catharina M. Mulders-Manders, Chantal P. Bleeker-Rovers, Wim J.G. Oyen Source Type: research
Metabolic Tumor Volume Metrics in Lymphoma
Although visual assessment using the Deauville criteria is strongly recommended by guidelines for treatment response monitoring in all FDG-avid lymphoma histologies, the high rate of false-positives and concerns about interobserver variability have motivated the development of quantitative tools to facilitate objective measurement of tumor response in both routine and clinical trial settings. Imaging studies using functional quantitative measures play a significant role in profiling oncologic processes. (Source: Seminars in Nuclear Medicine)
Source: Seminars in Nuclear Medicine - November 29, 2017 Category: Nuclear Medicine Authors: Lale Kostakoglu, St éphane Chauvie Source Type: research
Letter from the Editors
The editors are delighted to welcome Dr Lale Kostakoglu as our guest editor for this issue on lymphoma. Dr Kostakoglu is one of the pioneers in the application of Nuclear Medicine techniques to the study of lymphoma and its management. A variety of different radiopharmaceuticals have been applied to the management of this potentially curable disease, but only FDG-PET has achieved a truly tangible success as evidenced by the articles in this issue of the Seminars that show the wide breadth of its utilization. (Source: Seminars in Nuclear Medicine)
Source: Seminars in Nuclear Medicine - November 29, 2017 Category: Nuclear Medicine Authors: M. Donald Blaufox, Leonard M. Freeman Source Type: research
Radionuclide Imaging of Infection and Inflammation in Children: a Review
With the exception of radiolabeled monoclonal antibodies, antibody fragments and radiolabeled peptides which have seen little application in the pediatric population, the nuclear medicine imaging procedures used in the evaluation of infection and inflammation are the same for both adults and children. These procedures include (1) either a two- or a three-phase bone scan using technetium-99m methylene diphosphonate; (2) Gallium 67-citrate; (3) in vitro radiolabeled white blood cell imaging (using 111Indium-oxine or 99mTechnetium hexamethyl-propylene-amine-oxime –labeled white blood cells); and (4) hybrid imaging with 18F-...
Source: Seminars in Nuclear Medicine - November 28, 2017 Category: Nuclear Medicine Authors: Marguerite T. Parisi, Jeffrey P. Otjen, A. Luana Stanescu, Barry L. Shulkin Source Type: research
Tuberculosis
(TB) is currently the world's leading cause of infectious mortality. Imaging plays an important role in the management of this disease. The complex immune response of the human body to Mycobacterium tuberculosis results in a wide array of clinical manifestations, making clinical and radiological diagnosis challenging. 18F-FDG-PET/CT is very sensitive in the early detection of TB in most parts of the body; however, the lack of specificity is a major limitation. 18F-FDG-PET/CT images the whole body and provides a pre-therapeutic metabolic map of the infection, enabling clinicians to accurately assess the burden of disease. ...
Source: Seminars in Nuclear Medicine - November 16, 2017 Category: Nuclear Medicine Authors: Alfred O. Ankrah, Andor W.J.M. Glaudemans, Alex Maes, Christophe Van de Wiele, Rudi A.J.O. Dierckx, Mariza Vorster, Mike M. Sathekge Source Type: research
Monitoring Response to Therapy
Monitoring response to treatment is a key element in the management of infectious diseases, yet controversies still persist on reliable biomarkers for noninvasive response evaluation. Considering the limitations of invasiveness of most diagnostic procedures and the issue of expression heterogeneity of pathology, molecular imaging is better able to assay in vivo biologic processes noninvasively and quantitatively. The usefulness of 18F-FDG-PET/CT in assessing treatment response in infectious diseases is more promising than for conventional imaging. (Source: Seminars in Nuclear Medicine)
Source: Seminars in Nuclear Medicine - November 13, 2017 Category: Nuclear Medicine Authors: Mike M. Sathekge, Alfred O. Ankrah, Ismaheel Lawal, Mariza Vorster Source Type: research
Guest Editorial
This issue is dedicated to the applications of imaging with FDG-PET/CT in patients with lymphoma, a diagnostic modality that has gained a universal acceptance, particularly after the adoption of the recently published Lugano guidelines.1,2 (Source: Seminars in Nuclear Medicine)
Source: Seminars in Nuclear Medicine - October 27, 2017 Category: Nuclear Medicine Authors: Lale Kostakoglu Source Type: research
PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up
FDG-PET/CT is an established first-line diagnostic imaging tool used in the staging of most lymphomas and for post-therapy response assessment in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL). Many of the subtypes of lymphoid neoplasms classified by the World Health Organization demonstrate significant FDG-avidity or uptake; however, many guidelines and Lugano classification do not recommend the use of FDG-PET/CT in assessing response to therapy for these non-HL, non-DLBCL subtypes as a first-line diagnostic tool. (Source: Seminars in Nuclear Medicine)
Source: Seminars in Nuclear Medicine - October 25, 2017 Category: Nuclear Medicine Authors: Shawn Karls, Hina Shah, Heather Jacene Source Type: research
Interim FDG-PET Imaging in Lymphoma
In the present article, the authors reviewed the rationale of FDG-PET/CT performed at an interim time point during therapy (iPET), focusing on the transition from standard, anatomical assessment of tumor shrinkage with CT to document a chemotherapy response, to the use of functional imaging with PET to assess chemosensitivity of the individual tumor. The prognostic or predictive role of iPET in different lymphoma subsets has been reviewed, with particular emphasis on early and advanced-stage Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, extranodal natural killer/T-cell lymphoma, and primary m...
Source: Seminars in Nuclear Medicine - October 13, 2017 Category: Nuclear Medicine Authors: Andrea Gallamini, Colette Zwarthoed Source Type: research
